Correction: Microenvironment-responsive multifunctional hydrogels with spatiotemporal sequential release of tailored recombinant human collagen type III for the rapid repair of infected chronic diabetic wounds

Correction for ‘Microenvironment-responsive multifunctional hydrogels with spatiotemporal sequential release of tailored recombinant human collagen type III for the rapid repair of infected chronic diabetic wounds’ by Cheng Hu et al., J. Mater. Chem. B, 2021, 9, 9684–9699, DOI: 10.1039/D1TB02170B.

Download Full-text

Microenvironment-responsive multifunctional hydrogels with spatiotemporal sequential release of tailored recombinant human collagen type III for the rapid repair of infected chronic diabetic wounds

Journal of Materials Chemistry B ◽

10.1039/d1tb02170b ◽

2021 ◽

Author(s):

Cheng Hu ◽

Wenqi Liu ◽

Linyu Long ◽

Zhicun Wang ◽

Yihui Yuan ◽

...

Keyword(s):

Controlled Release ◽

Collagen Type ◽

Collagen Type Iii ◽

Rapid Repair ◽

Type Iii ◽

Sequential Release ◽

Human Collagen ◽

Diabetic Wounds ◽

Therapeutic Substance

A brand-new tailored hCol III-based microenvironment-responsive hydrogel could effectively accelerate the repair and regeneration of chronic diabetic wounds by a programmed controlled release of therapeutic substance approach.

Download Full-text

High-Resolution Bioprinting of Recombinant Human Collagen Type III

Polymers ◽

10.3390/polym13172973 ◽

2021 ◽

Vol 13 (17) ◽

pp. 2973

Author(s):

Rory Gibney ◽

Jennifer Patterson ◽

Eleonora Ferraris

Keyword(s):

Tissue Engineering ◽

High Resolution ◽

Collagen Type ◽

Thin Layers ◽

Corneal Tissue ◽

Collagen Type Iii ◽

Type Iii ◽

Pure Collagen ◽

Human Collagen ◽

Visible Wavelengths

The development of commercial collagen inks for extrusion-based bioprinting has increased the amount of research on pure collagen bioprinting, i.e., collagen inks not mixed with gelatin, alginate, or other more common biomaterial inks. New printing techniques have also improved the resolution achievable with pure collagen bioprinting. However, the resultant collagen constructs still appear too weak to replicate dense collagenous tissues, such as the cornea. This work aims to demonstrate the first reported case of bioprinted recombinant collagen films with suitable optical and mechanical properties for corneal tissue engineering. The printing technology used, aerosol jet® printing (AJP), is a high-resolution printing method normally used to deposit conductive inks for electronic printing. In this work, AJP was employed to deposit recombinant human collagen type III (RHCIII) in overlapping continuous lines of 60 µm to form thin layers. Layers were repeated up to 764 times to result in a construct that was considered a few hundred microns thick when swollen. Samples were subsequently neutralised and crosslinked using EDC:NHS crosslinking. Nanoindentation and absorbance measurements were conducted, and the results show that the AJP-deposited RHCIII samples possess suitable mechanical and optical properties for corneal tissue engineering: an average effective elastic modulus of 506 ± 173 kPa and transparency ≥87% at all visible wavelengths. Circular dichroism showed that there was some loss of helicity of the collagen due to aerosolisation. SDS-PAGE and pepsin digestion were used to show that while some collagen is degraded due to aerosolisation, it remains an inaccessible substrate for pepsin cleavage.

Download Full-text

Demonstration by Immunofluorescence That Host Collagen Replaces Dermal Microimplants of Bovine Collagen

The American Journal of Cosmetic Surgery ◽

10.1177/074880688700400103 ◽

1987 ◽

Vol 4 (1) ◽

pp. 15-19 ◽

Cited By ~ 3

Author(s):

Karen E. Burke ◽

Gail Naughton

Keyword(s):

Host Response ◽

Collagen Type ◽

Type I ◽

Collagen Type Iii ◽

Type Iii ◽

Bovine Collagen ◽

Collagen Implant ◽

Human Dermis ◽

Dermal Collagen ◽

Human Collagen

It has previously been demonstrated with sequential biopsies analyzed by standard histological stains, immunofluorescence, and electron microscopy that an injectable form of type I bovine dermal collagen (Zyderm® Collagen Implant, or ZCI) in the human dermis stimulates a host response. This host response results in implant degradation and replacement by newly generated host collagen. However, definitive proof that the human collagen is deposited directly on the bovine collagen implants is lacking. This study reports for the first time simultaneous labeling of the ZCI with fluorescein and the host collagen type III with rhodamine. These experiments show that human collagen type III is synthesized directly on the bovine collagen implants.

Download Full-text

Development of a recombinant human collagen-type III based hemostat

Journal of Biomedical Materials Research ◽

10.1002/jbm.b.20030 ◽

2004 ◽

Vol 69B (1) ◽

pp. 18-24 ◽

Cited By ~ 15

Author(s):

C. Yang ◽

P. Hillas ◽

J. Tang ◽

J. Balan ◽

H. Notbohm ◽

...

Keyword(s):

Collagen Type ◽

Collagen Type Iii ◽

Type Iii ◽

Human Collagen

Download Full-text

Data mining-based study of collagen type III alpha 1 (COL3A1) prognostic value and immune exploration in pan-cancer

Bioengineered ◽

10.1080/21655979.2021.1949838 ◽

2021 ◽

Vol 12 (1) ◽

pp. 3634-3646

Author(s):

Hanyu Zhang ◽

Cheng Ding ◽

Yatong Li ◽

Cheng Xing ◽

Shunda Wang ◽

...

Keyword(s):

Data Mining ◽

Prognostic Value ◽

Collagen Type ◽

Collagen Type Iii ◽

Type Iii ◽

Pan Cancer

Download Full-text

Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab

Scientific Reports ◽

10.1038/s41598-020-79608-0 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Neel I. Nissen ◽

Stephanie Kehlet ◽

Mogens K. Boisen ◽

Maria Liljefors ◽

Christina Jensen ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Collagen Type ◽

Performance Status ◽

Drug Uptake ◽

Collagen Type Iii ◽

Serum Samples ◽

Type Iii ◽

Poor Treatment ◽

And Performance

AbstractA desmoplastic colorectal cancer stroma, characterized by excess turnover of the cancer-associated fibroblast derived collagens type III and VI, can lead to reduced drug-uptake and poor treatment response. We investigated the association between biomarkers of collagen type III and VI and overall survival (OS) in patients with metastatic colorectal cancer (mCRC). Serum samples were collected from 252 patients with mCRC prior to treatment with bevacizumab and chemotherapy. Serum concentrations of biomarkers reflecting formation of collagen type III (PRO-C3) and VI (PRO-C6) and degradation of collagen type VI (C6M and C6Mα3) were determined by ELISA. The biomarkers were evaluated for associations with OS, individually, combined, and after adjusting for carcinoembryonic antigen (CEA), lactate dehydrogenase (LDH) and performance status (PS). High baseline levels (> median) of each collagen biomarker were significantly associated with shorter OS (PRO-C3: HR = 2.0, 95%CI = 1.54–2.63; PRO-C6: HR = 1.6, 95%CI = 1.24–2.11; C6M: HR = 1.4, 95%CI = 1.05–1.78; C6Mα3: HR = 1.6, 95%CI = 1.16–2.07). PRO-C3 and PRO-C6 remained significant after adjustment for CEA, LDH and PS. Weak correlations were seen between the collagen biomarkers (r = 0.03–0.59) and combining all improved prognostic capacity (HR = 3.6, 95%CI = 2.30–5.76). Collagen biomarkers were predictive of shorter OS in patients with mCRC. This supports that collagen- and CAF biology is important in CRC.

Download Full-text